This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Andrew Butcher describes why securing stakeholder buy-in to high-cost new therapies is critical to managing the pharmaceutical industry’s reputation in the November/December 2015 issue of PharmaVOICE. To read more, click here.
The United States is the world leader in innovative drug development, supporting patients and health systems globally by advancing the creation of new cures...
CRA’s Life Sciences Practice focuses on global policy, commercialization, and market access issues dedicated to orphan drug issues, including orphan evidence...
Looking back 10 years, the rare disease space has significantly evolved with a plethora of innovative orphan drug launches and many patients gaining access to...
Tim Wilsdon is speaking during the session. For more information on this event, click here.
